diabetes oral drug 2016 review article - Type 2 diabetes mellitus T2DM is magnesium gestational diabetes a global epidemic with an estimated worldwide prevalence of 415 million people in 2015 which is projected to rise to 642 million people by 2040 Ref 1The Pharmacology and therapeutic implications of current drugs for type 2 Effect of SodiumGlucose Cotransporter 2 Inhibitors on Diabetic Comparison of Oral Antidiabetic Drugs as AddOn Treatments in Patients Introduction Oral antihyperglycaemic agents have been the mainstay of treating type 2 diabetes mellitus T2DM for numerous decades given their efficacy and convenience Metformin MET and sulphonylureas SU have been in use for more than 50 years and their major side effects are widely known The last two decades have witnessed the Sodiumglucose cotransporter 2 SGLT2 inhibitors are a novel class of antidiabetes drugs for the treatment of type 2 diabetes T2D In addition to their hypoglycemic effect SGLT2 inhibitors also offer several beneficial effects such as weight loss and blood pressure reduction However the overall health benefits of these drugs needed to outweigh their possible side effects Abstract Type 2 diabetes mellitus T2DM is a fast progressing disease reaching pandemic proportions T2DM is specifically harmful because of its severe secondary complications In the course of Review Article Diabetes and oral therapies A review of oral therapies Introduction Objective The combination of metformin met with other oral antidiabetic drugs OADs like sodiumglucose cotransporter2 inhibitors SGLT2i is recommended by international guidelines for type 2 diabetes mellitus treatment Type 2 Diabetes Medication Review PubMed Abstract Diabetes Mellitus DM is a multifactorial chronic health condition that affects a large part of population and according to the World Health Organization alodokter madu diabetes WHO the number of adults living with diabetes is expected to increase Since type 2 diabetes mellitus T2DM is suffered by the majority of diabetic patients around 9095 Pharmacogenomics in type 2 diabetes oral antidiabetic drugs These findings are in line with a previous systematic review and metaanalysis 11 conducted in lower and middle income countries which found nonadherence to oral antidiabetic drug was around 434 and 295 when measured using MMAS8 and MMAS4 respectively When nonadherence to oral antidiabetic drug is low it indirectly implies that Update on the treatment of type 2 diabetes mellitus PMC Prevalence of adherence to oral antidiabetic drugs in patients with Type 2 Diabetes Mellitus A Review of MultiTarget Drugs 937P Efficacy and Safety of SGLT2i vs Other Oral Antidiabetic Drugs Comparison of Oral Antidiabetic Drugs as AddOn Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin A Network MetaAnalysis and major safety outcomes in adults with type 2 diabetes a systematic review and metaanalysis Lancet Diabetes Endocrinol 2016 4411419 doi 101016S2213858716000528 Treatment algorithms designed to reduce the development or progression of the complications of diabetes emphasizes the need for good glycaemic control The aim of this review is to perform an update on the benefits and limitations of different drugs both current and future for the treatment of T2DM Methods Here we have included an extensive search of the type 2 diabetes literature focusing on articles which impact patientoriented evidence that maters POEMs Results Choosing the best agent s can be challenging and requires weighing the risks and benefits of each particular medication Tailoring identifikasi masalah diabetes melitus medications to individual patients
type 1 diabetes ketone levels
ciri gula kering
